Hypereosinophiliesyndrome

Zusammenfassung

In den vergangenen Jahren wurden zahlreiche neue Erkenntnisse zur Biologie eosinophiler Granulozyten, ihrer Rolle für die Gesundheit und bei Krankheiten gewonnen. Differenzierte Kenntnisse zur Pathogenese, neue diagnostische Methoden und Therapeutika haben das Verständnis zur Hypereosinophilie und damit assoziierten Erkrankungen und Syndromen fundamental geändert. In dieser Übersichtsarbeit diskutieren wir die gegenwärtige Klassifikation der Hypereosinophiliesyndrome und neue Therapieansätze.

Abstract

In recent years, the knowledge on eosinophil biology as well as their role in health and disease has dramatically increased. Differential insights in the pathogenesis, new diagnostic techniques and therapeutic substances have modified our understanding of hypereosinophilia and associated diseases and syndromes. In this review, we discuss the current classification of hypereosinophilic syndromes as well as therapeutic strategies.

• Literatur

• 1 Chusid MJ, Dale DC, West BC et al. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54: 1-27
• 2 Simon HU, Rothenberg ME, Bochner BS et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010; 126: 45-49
• 3 Straumann A, Simon HU. The physiological and pathophysiological roles of eosinophils in the gastrointestinal tract. Allergy 2004; 59: 15-25
• 4 Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. Allergy 2004; 59: 561-570
• 5 Blanchard C, Rothenberg ME. Biology of the eosinophil. Adv Immunol 2009; 101: 81-121
• 6 Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000; 105: 651-663
• 7 Yousefi S, Gold JA, Andina N et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med 2008; 14: 949-953
• 8 Morshed M, Yousefi S, Stockle C et al. Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps. Allergy 2012; 67: 1127-1137
• 9 Dworski R, Simon HU, Hoskins A et al. Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways. J Allergy Clin Immunol 2011; 127: 1260-1266
• 10 Kerstan A, Simon HU, Yousefi S et al. Extensive accumulation of eosinophil extracellular traps in bullous delayed-pressure urticaria: a pathophysiological link?. Br J Dermatol 2012; 166: 1151-1152
• 11 Simon D, Hoesli S, Roth N et al. Eosinophil extracellular DNA traps in skin diseases. J Allergy Clin Immunol 2011; 127: 194-199
• 12 Simon D, Simon HU, Yousefi S. Extracellular DNA traps in allergic, infectious, and autoimmune diseases. Allergy 2013; 68: 409-416
• 13 Roth N, Stadler S, Lemann M et al. Distinct eosinophil cytokine expression patterns in skin diseases – the possible existence of functionally different eosinophil subpopulations. Allergy 2011; 66: 1477-1486
• 14 Valent P. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. Blood Rev 2009; 23: 157-165
• 15 Valent P, Gleich GJ, Reiter A et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol 2012; 5: 157-176
• 16 Valent P, Klion AD, Horny HP et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012; 130: 607-612
• 17 Wilkins HJ, Crane MM, Copeland K et al. Hypereosinophilic syndrome: an update. Am J Hematol 2005; 80: 148-157
• 18 Simon D, Simon HU. Eosinophilic disorders. J Allergy Clin Immunol 2007; 119: 1291-1300
• 19 Fridlender ZG, Simon HU, Shalit M. Metastatic carcinoma presenting with concomitant eosinophilia and thromboembolism. Am J Med Sci 2003; 326: 98-101
• 20 Simon HU, Plotz SG, Dummer R et al. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999; 341: 1112-1120
• 21 Simon HU, Plotz SG, Simon D et al. Clinical and immunological features of patients with interleukin-5-producing T cell clones and eosinophilia. Int Arch Allergy Immunol 2001; 124: 242-245
• 22 Lammel V, Stoeckle C, Padberg B et al. Hypereosinophilia driven by GM-CSF in large-cell carcinoma of the lung. Lung Cancer 2012; 76: 493-495
• 23 Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22
• 24 Wadleigh M, Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol 2010; 91: 174-179
• 25 Simon D, Wardlaw A, Rothenberg ME. Organ-specific eosinophilic disorders of the skin, lung, and gastrointestinal tract. J Allergy Clin Immunol 2010; 126: 3-13
• 26 Stoeckle C, Simon HU. CD8(+) T cells producing IL-3 and IL-5 in non-IgE-mediated eosinophilic diseases. Allergy 2013; 68: 1622-1625
• 27 Simon HU, Klion A. Therapeutic approaches to patients with hypereosinophilic syndromes. Semin Hematol 2012; 49: 160-170
• 28 Ogbogu PU, Bochner BS, Butterfield JH et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009; 124: 1319-1325
• 29 Klion AD, Noel P, Akin C et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101: 4660-4666
• 30 Salemi S, Yousefi S, Simon D et al. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Allergy 2009; 64: 913-918
• 31 Simon D, Salemi S, Yousefi S et al. Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. J Allergy Clin Immunol 2008; 121: 1054-1056
• 32 Kim S, Marigowda G, Oren E et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125: 1336-1343
• 33 Plotz SG, Simon HU, Darsow U et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003; 349: 2334-2339
• 34 Rothenberg ME, Klion AD, Roufosse FE et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008; 358: 1215-1228